Healthcare provider profile · identity verified

Eugene F Tan, MD

Allopathic & Osteopathic Physicians|Family Medicine · CRAWFORDSVILLE, IN · NPI 1295061802

Profile state: payments and partd Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

CMS Open Payments records show Eugene F Tan, MD received $117.72 in general payments during 2025 across 1 reported records.

AstraZeneca Pharmaceuticals LP accounted for 100.0% of that reported general-payment amount.

The Open Payments records used for this analysis explicitly named 1 associated product.

A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga.

AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BEVESPI AEROSPHERE as an associated drug or biological on 763 records involving 473 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Bevespi Aerosphere by this doctor in 2024.

AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Brilinta by this doctor in 2024.

AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Farxiga by this doctor in 2024.

AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Symbicort by this doctor in 2024.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

$117.72

1 reported records · 1 companies

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Who paid this doctor?

Companies in 2025 General Payments

Reported company	Canonical company	Amount	Share	Records	Year
AstraZeneca Pharmaceuticals LP	Unresolved — no canonical attribution shown	$117.72	100.0%	1	2025

What were the payments for?

Payment categories

Category	Amount	Records
Food and Beverage	$117.72	1

A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.

Analysis 1 · Payment-linked products

Products named in Open Payments records

Reported product	Type	Reported company	Related amount*	Records	Year
FARXIGA Normalized: farxiga	Drug	AstraZeneca Pharmaceuticals LP	$117.72	1	2025
Source payment records 2025-02-26 · AstraZeneca Pharmaceuticals LP · $117.72 · Open Payments source

* Product-associated amounts are non-additive because one payment record may name more than one product.

These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.

Public prescribing for products named in payments

Open Payments product	Payment year	Part D brand	Part D year	Claims	Match method	Source
FARXIGA farxiga	2025	Farxiga	2024	20 Beneficiary count suppressed	exact normalized	Medicare Part D

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

Paying company	Payment year	Drug reported by same entity	Open Payments evidence	Part D	Claims	Beneficiaries
AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference	2025	BEVESPI AEROSPHERE open payments reported associated product	CMS Open Payments — General Payments 763 supporting records · 473 recipient NPIs · example record 1206131384	Bevespi Aerosphere · 2024 Exact normalized brand match · 1 Part D row	21	suppressed by CMS
AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference	2025	BRILINTA open payments reported associated product	CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430	Brilinta · 2024 Exact normalized brand match · 1 Part D row	12	suppressed by CMS
AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference	2025	FARXIGA open payments reported associated product	CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362	Farxiga · 2024 Exact normalized brand match · 1 Part D row	20	suppressed by CMS
AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference	2025	SYMBICORT open payments reported associated product	CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610	Symbicort · 2024 Exact normalized brand match · 1 Part D row	36	suppressed by CMS

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	1277	328
Levothyroxine Sodium	Levothyroxine Sodium	636	159
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	598	92
Gabapentin	Gabapentin	552	129
Amlodipine Besylate	Amlodipine Besylate	519	151
Lisinopril	Lisinopril	475	137
Omeprazole	Omeprazole	447	122
Pantoprazole Sodium	Pantoprazole Sodium	423	114
Losartan Potassium	Losartan Potassium	415	112
Metformin Hcl	Metformin Hcl	388	100
Furosemide	Furosemide	370	104
Sertraline Hcl	Sertraline Hcl	368	69
Albuterol Sulfate Hfa	Albuterol Sulfate	364	107
Metoprolol Succinate	Metoprolol Succinate	361	110
Metoprolol Tartrate	Metoprolol Tartrate	312	79
Trazodone Hcl	Trazodone Hcl	307	75
Ozempic	Semaglutide	280	51
Eliquis	Apixaban	279	56
Clopidogrel	Clopidogrel Bisulfate	265	65
Rosuvastatin Calcium	Rosuvastatin Calcium	264	85
Alendronate Sodium	Alendronate Sodium	245	78
Tramadol Hcl	Tramadol Hcl	235	37
Donepezil Hcl	Donepezil Hcl	234	50
Tamsulosin Hcl	Tamsulosin Hcl	229	70
Jardiance	Empagliflozin	225	45
Prednisone	Prednisone	221	116
Hydrochlorothiazide	Hydrochlorothiazide	196	59
Potassium Chloride	Potassium Chloride	195	46
Clonazepam	Clonazepam	192	27
Memantine Hcl	Memantine Hcl	190	41
Alprazolam	Alprazolam	181	25
Simvastatin	Simvastatin	180	50
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	179	47
Buspirone Hcl	Buspirone Hcl	178	49
Carvedilol	Carvedilol	177	50
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	177	32
Spironolactone	Spironolactone	174	40
Celecoxib	Celecoxib	172	50
Ondansetron Hcl	Ondansetron Hcl	169	33
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	160	42
Clonidine Hcl	Clonidine Hcl	157	42
Escitalopram Oxalate	Escitalopram Oxalate	146	35
Lorazepam	Lorazepam	146	29
Duloxetine Hcl	Duloxetine Hcl	139	41
Ezetimibe	Ezetimibe	138	41
Metformin Hcl Er	Metformin Hcl	137	42
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	135	38
Pravastatin Sodium	Pravastatin Sodium	124	31
Fluticasone Propionate	Fluticasone Propionate	117	53
Allopurinol	Allopurinol	116	31
Fluoxetine Hcl	Fluoxetine Hcl	115	36
Mounjaro	Tirzepatide	109	28
Pregabalin	Pregabalin	106	19
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	105	17
Famotidine	Famotidine	102	29
Montelukast Sodium	Montelukast Sodium	102	27
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	100	79
Valsartan	Valsartan	97	33
Zolpidem Tartrate	Zolpidem Tartrate	95	19
Paroxetine Hcl	Paroxetine Hcl	93	21
Topiramate	Topiramate	93	23
Tresiba Flextouch U-100	Insulin Degludec	91	14
Glimepiride	Glimepiride	86	23
Cephalexin	Cephalexin	83	48
Venlafaxine Hcl Er	Venlafaxine Hcl	83	17
Warfarin Sodium	Warfarin Sodium	81	15
Hydroxyzine Hcl	Hydroxyzine Hcl	75	26
Januvia	Sitagliptin Phosphate	75	14
Ondansetron Odt	Ondansetron	73	19
Doxycycline Hyclate	Doxycycline Hyclate	72	32
Quetiapine Fumarate	Quetiapine Fumarate	72	16
Glipizide Er	Glipizide	71	20
Xarelto	Rivaroxaban	70	suppressed
Bupropion Xl	Bupropion Hcl	68	17
Mirtazapine	Mirtazapine	68	24
Atenolol	Atenolol	66	21
Bupropion Hcl Sr	Bupropion Hcl	63	19
Olanzapine	Olanzapine	63	suppressed
Torsemide	Torsemide	61	13
Trulicity	Dulaglutide	61	16
Nystatin	Nystatin	60	17
Ropinirole Hcl	Ropinirole Hcl	60	19
Citalopram Hbr	Citalopram Hydrobromide	58	17
Carbidopa-Levodopa	Carbidopa/Levodopa	57	suppressed
Tizanidine Hcl	Tizanidine Hcl	57	13
Stiolto Respimat	Tiotropium Br/Olodaterol Hcl	55	suppressed
Baclofen	Baclofen	54	suppressed
Finasteride	Finasteride	54	15
Pramipexole Dihydrochloride	Pramipexole Di-Hcl	54	12
Valsartan-Hydrochlorothiazide	Valsartan/Hydrochlorothiazide	54	19
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	53	30
Solifenacin Succinate	Solifenacin Succinate	53	21
Autoshield Duo Pen Needle	Pen Needle,dual Safety,diabetc	52	13
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	52	13
Meloxicam	Meloxicam	51	16
Novolog Flexpen	Insulin Aspart	50	12
Amitriptyline Hcl	Amitriptyline Hcl	49	13
Nano 2nd Gen Pen Needle	Pen Needle, Diabetic	49	18
Carbamazepine	Carbamazepine	48	suppressed
Myrbetriq	Mirabegron	48	12
Diazepam	Diazepam	47	suppressed
Diclofenac Sodium	Diclofenac Sodium	47	20
Dicyclomine Hcl	Dicyclomine Hcl	46	12
Glipizide	Glipizide	46	16
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	45	15
Levetiracetam	Levetiracetam	43	suppressed
Doxycycline Monohydrate	Doxycycline Monohydrate	42	35
Lovastatin	Lovastatin	40	13
Klor-Con M20	Potassium Chloride	39	13
Amlodipine-Valsartan	Amlodipine Besylate/Valsartan	38	13
Hydrocortisone	Hydrocortisone	38	19
Lamotrigine	Lamotrigine	38	suppressed
Loperamide	Loperamide Hcl	38	11
Tresiba Flextouch U-200	Insulin Degludec	38	suppressed
Breztri Aerosphere	Budesonide/Glycopyr/Formoterol	37	suppressed
Eszopiclone	Eszopiclone	37	12
Clotrimazole-Betamethasone	Clotrimazole/Betamethasone Dip	36	21
Entresto	Sacubitril/Valsartan	36	suppressed
Insulin Glargine-Yfgn	Insulin Glargine-Yfgn	36	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	36	suppressed
Symbicort	Budesonide/Formoterol Fumarate	36	suppressed
Tradjenta	Linagliptin	35	suppressed
Amlodipine Besylate-Benazepril	Amlodipine Besylate/Benazepril	34	suppressed
Testosterone Cypionate	Testosterone Cypionate	34	suppressed
Esomeprazole Magnesium	Esomeprazole Magnesium	33	suppressed
Insulin Lispro Kwikpen U-100	Insulin Lispro	32	suppressed
Ipratropium-Albuterol	Ipratropium/Albuterol Sulfate	32	suppressed
Olmesartan-Hydrochlorothiazide	Olmesartan/Hydrochlorothiazide	31	suppressed
Amoxicillin	Amoxicillin	30	19
Azelastine Hcl	Azelastine Hcl	30	19
Dabigatran Etexilate	Dabigatran Etexilate Mesylate	30	suppressed
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	29	suppressed
Nifedipine Er	Nifedipine	29	suppressed
Clotrimazole	Clotrimazole	28	15
Diltiazem Hcl	Diltiazem Hcl	28	suppressed
Metoclopramide Hcl	Metoclopramide Hcl	27	suppressed
Acetaminophen-Codeine	Acetaminophen With Codeine	26	suppressed
Briviact	Brivaracetam	26	suppressed
Bisoprolol-Hydrochlorothiazide	Bisoprolol/Hydrochlorothiazide	25	suppressed
Fenofibrate	Fenofibrate Nanocrystallized	25	suppressed
Fentanyl	Fentanyl	25	suppressed
Hydralazine Hcl	Hydralazine Hcl	25	suppressed
Latanoprost	Latanoprost	25	suppressed
Naproxen	Naproxen	25	suppressed
Phenytoin Sodium Extended	Phenytoin Sodium Extended	25	suppressed
Primidone	Primidone	25	suppressed
Propranolol Hcl	Propranolol Hcl	25	suppressed
Amiodarone Hcl	Amiodarone Hcl	24	suppressed
Breo Ellipta	Fluticasone/Vilanterol	24	suppressed
Chlorthalidone	Chlorthalidone	24	suppressed
Colesevelam Hcl	Colesevelam Hcl	24	suppressed
Fluconazole	Fluconazole	24	16
Sodium Chloride	Sodium Chloride Irrig Solution	24	suppressed
Verapamil Er	Verapamil Hcl	24	suppressed
Enalapril Maleate	Enalapril Maleate	23	suppressed
Paxlovid (Eua)	Nirmatrelvir/Ritonavir	23	23
Sulfamethoxazole-Trimethoprim	Sulfamethoxazole/Trimethoprim	23	suppressed
Terbinafine Hcl	Terbinafine Hcl	23	13
Albuterol Sulfate	Albuterol Sulfate	22	suppressed
Paxlovid	Nirmatrelvir/Ritonavir	22	22
Bevespi Aerosphere	Glycopyrrolate/Formoterol Fum	21	suppressed
Meclizine Hcl	Meclizine Hcl	21	11
Midodrine Hcl	Midodrine Hcl	21	suppressed
Soliqua 100-33	Insulin Glargine/Lixisenatide	21	suppressed
Amantadine	Amantadine Hcl	20	suppressed
Divalproex Sodium	Divalproex Sodium	20	suppressed
Farxiga	Dapagliflozin Propanediol	20	suppressed
Humalog Kwikpen U-100	Insulin Lispro	20	suppressed
Atenolol-Chlorthalidone	Atenolol/Chlorthalidone	19	suppressed
Breyna	Budesonide/Formoterol Fumarate	19	suppressed
Klayesta	Nystatin	19	suppressed
Levocetirizine Dihydrochloride	Levocetirizine Dihydrochloride	19	suppressed
Mesalamine	Mesalamine	19	suppressed
Azithromycin	Azithromycin	18	14
Lansoprazole	Lansoprazole	18	suppressed
Levofloxacin	Levofloxacin	18	suppressed
Oxybutynin Chloride Er	Oxybutynin Chloride	18	suppressed
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	18	suppressed
Pen Needle	Pen Needle, Diabetic	18	suppressed
Pioglitazone Hcl	Pioglitazone Hcl	18	suppressed
Ultra-Fine Nano Pen Needle	Pen Needle, Diabetic	18	suppressed
Venlafaxine Hcl	Venlafaxine Hcl	18	suppressed
Zolpidem Tartrate Er	Zolpidem Tartrate	18	suppressed
Benazepril Hcl	Benazepril Hcl	17	suppressed
Gemtesa	Vibegron	17	suppressed
Irbesartan	Irbesartan	17	suppressed
Sulindac	Sulindac	17	suppressed
Varenicline Tartrate	Varenicline Tartrate	17	suppressed
Acyclovir	Acyclovir	16	suppressed
Calcitriol	Calcitriol	16	suppressed
Dulera	Mometasone/Formoterol	16	suppressed
Hydroxyzine Pamoate	Hydroxyzine Pamoate	16	suppressed
Insulin Degludec Pen (U-100)	Insulin Degludec	16	suppressed
Lidocaine	Lidocaine	16	suppressed
Nitroglycerin	Nitroglycerin	16	14
Aripiprazole	Aripiprazole	15	suppressed
Aspirin-Dipyridamole Er	Aspirin/Dipyridamole	15	suppressed
Combivent Respimat	Ipratropium/Albuterol Sulfate	15	suppressed
Wixela Inhub	Fluticasone Propion/Salmeterol	15	suppressed
Digoxin	Digoxin	14	suppressed
Fenofibrate	Fenofibrate	14	suppressed
Lubiprostone	Lubiprostone	14	suppressed
Mupirocin	Mupirocin	14	suppressed
Ofloxacin	Ofloxacin	14	13
Toujeo Solostar	Insulin Glargine,hum.Rec.Anlog	14	suppressed
Bumetanide	Bumetanide	13	suppressed
Cefdinir	Cefdinir	13	suppressed
Clonidine	Clonidine	13	suppressed
Doxazosin Mesylate	Doxazosin Mesylate	13	suppressed
Droplet Pen Needle	Pen Needle, Diabetic	13	suppressed
Livalo	Pitavastatin Calcium	13	suppressed
Morphine Sulfate Er	Morphine Sulfate	13	suppressed
Oxcarbazepine	Oxcarbazepine	13	suppressed
Rivastigmine	Rivastigmine	13	suppressed
Rizatriptan	Rizatriptan Benzoate	13	suppressed
Temazepam	Temazepam	13	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	13	suppressed
Trimethoprim	Trimethoprim	13	suppressed
Basaglar Kwikpen U-100	Insulin Glargine,hum.Rec.Anlog	12	suppressed
Brilinta	Ticagrelor	12	suppressed
Buprenorphine	Buprenorphine	12	suppressed
Ciprofloxacin Hcl	Ciprofloxacin Hcl	12	11
Dalfampridine Er	Dalfampridine	12	suppressed
Dextroamphetamine-Amphet Er	Dextroamphetamine/Amphetamine	12	suppressed
Insulin Aspart Flexpen	Insulin Aspart	12	suppressed
Lacosamide	Lacosamide	12	suppressed
Lantus	Insulin Glargine,hum.Rec.Anlog	12	suppressed
Linzess	Linaclotide	12	suppressed
Methocarbamol	Methocarbamol	12	suppressed
Methylprednisolone	Methylprednisolone	12	suppressed
Mometasone Furoate	Mometasone Furoate	12	suppressed
Nortriptyline Hcl	Nortriptyline Hcl	12	suppressed
Olmesartan Medoxomil	Olmesartan Medoxomil	12	suppressed
Propranolol Hcl Er	Propranolol Hcl	12	suppressed
Ranolazine Er	Ranolazine	12	suppressed
Budesonide	Budesonide	11	suppressed
Desvenlafaxine Succinate Er	Desvenlafaxine Succinate	11	suppressed
Epinephrine	Epinephrine	11	suppressed
Ibuprofen	Ibuprofen	11	suppressed
Insulin Lispro	Insulin Lispro	11	suppressed
Methadone Hcl	Methadone Hcl	11	suppressed
Toujeo Max Solostar	Insulin Glargine,hum.Rec.Anlog	11	suppressed
Valacyclovir	Valacyclovir Hcl	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	$117.72 · 1 records	AstraZeneca Pharmaceuticals LP	FARXIGA	4	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

What role, if any, does Farxiga play in your treatment recommendations for me?
How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error